Bepirovirsen Accepted for Priority Review and Granted Breakthrough Therapy Designation by the U.S. FDA
April 28, 2026
April 28, 2026
LONDON, England, April 28 -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on April 27, 2026:
* * *
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
* Regulatory application supported by phase III B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B
* Breakthrough Therapy De . . .
* * *
Bepirovirsen accepted for priority review and granted Breakthrough Therapy Designation by the US FDA
* Regulatory application supported by phase III B-Well trials demonstrating statistically significant and clinically meaningful functional cure rates in chronic hepatitis B
* Breakthrough Therapy De . . .